Cargando…

Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study

PURPOSE: In the study, patients with unresectable hepatocellular carcinoma (uHCC) were treated with either transcatheter chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitor (TACE-L-P) or TACE combined with lenvatinib (TACE-L). We compared the efficacy and safety of TACE-L-P with...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Hui, Yang, Tiequan, Qiu, Guangpin, Liu, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492540/
https://www.ncbi.nlm.nih.gov/pubmed/37691972
http://dx.doi.org/10.2147/JHC.S423684
_version_ 1785104277910323200
author Yang, Hui
Yang, Tiequan
Qiu, Guangpin
Liu, Jie
author_facet Yang, Hui
Yang, Tiequan
Qiu, Guangpin
Liu, Jie
author_sort Yang, Hui
collection PubMed
description PURPOSE: In the study, patients with unresectable hepatocellular carcinoma (uHCC) were treated with either transcatheter chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitor (TACE-L-P) or TACE combined with lenvatinib (TACE-L). We compared the efficacy and safety of TACE-L-P with TACE-L, and analyzed factors affecting prognosis. MATERIALS AND METHODS: A total of 122 patients were treated with either TACE-L-P (n = 64) or TACE-L (n = 58), and their data was collected and analyzed. We assessed tumor response, progression-free survival (PFS), prognostic factors for PFS and adverse events (AEs) to compare the efficacy and safety of TACE-L-P with TACE-L for patients with uHCC. RESULTS: TACE-L-P group’s patients had a better objective response rate (ORR) (57.8% vs 41.4%, P = 0.047) and a better disease control rate (93.7% vs 81%, P = 0.013), as long as a longer median progression-free survival (PFS) (8 months vs 4.6 months, HR: 0.461; 95% CI: [0.314–0.675]; P = 0.001) than TACE-L group’s patients. According to multivariate analysis, independent prognostic factors for PFS included treatment option (TACE-L-P / TACE-L; RH = 0.461; 95% CI [0.314–0.675]; P = 0.001), PVTT (Yes/No; RH =1 0.599;95% CI [1 0.095–2 0.336]; P=0 0.017), extrahepatic metastasis (Yes/No; RH=1 0.847;95% CI [1 0.176 −2 0.909]; P=0 0.008). AEs in TACE-L-P group was similar with TACE-L group. CONCLUSION: TACE-L-P has more promising clinical outcomes in patients with uHCC than TACE-L, and their safety is similar.
format Online
Article
Text
id pubmed-10492540
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104925402023-09-10 Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study Yang, Hui Yang, Tiequan Qiu, Guangpin Liu, Jie J Hepatocell Carcinoma Original Research PURPOSE: In the study, patients with unresectable hepatocellular carcinoma (uHCC) were treated with either transcatheter chemoembolization (TACE) combined with lenvatinib and PD-(L)1 inhibitor (TACE-L-P) or TACE combined with lenvatinib (TACE-L). We compared the efficacy and safety of TACE-L-P with TACE-L, and analyzed factors affecting prognosis. MATERIALS AND METHODS: A total of 122 patients were treated with either TACE-L-P (n = 64) or TACE-L (n = 58), and their data was collected and analyzed. We assessed tumor response, progression-free survival (PFS), prognostic factors for PFS and adverse events (AEs) to compare the efficacy and safety of TACE-L-P with TACE-L for patients with uHCC. RESULTS: TACE-L-P group’s patients had a better objective response rate (ORR) (57.8% vs 41.4%, P = 0.047) and a better disease control rate (93.7% vs 81%, P = 0.013), as long as a longer median progression-free survival (PFS) (8 months vs 4.6 months, HR: 0.461; 95% CI: [0.314–0.675]; P = 0.001) than TACE-L group’s patients. According to multivariate analysis, independent prognostic factors for PFS included treatment option (TACE-L-P / TACE-L; RH = 0.461; 95% CI [0.314–0.675]; P = 0.001), PVTT (Yes/No; RH =1 0.599;95% CI [1 0.095–2 0.336]; P=0 0.017), extrahepatic metastasis (Yes/No; RH=1 0.847;95% CI [1 0.176 −2 0.909]; P=0 0.008). AEs in TACE-L-P group was similar with TACE-L group. CONCLUSION: TACE-L-P has more promising clinical outcomes in patients with uHCC than TACE-L, and their safety is similar. Dove 2023-09-05 /pmc/articles/PMC10492540/ /pubmed/37691972 http://dx.doi.org/10.2147/JHC.S423684 Text en © 2023 Yang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yang, Hui
Yang, Tiequan
Qiu, Guangpin
Liu, Jie
Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
title Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
title_full Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
title_fullStr Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
title_full_unstemmed Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
title_short Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study
title_sort efficacy and safety of tace combined with lenvatinib and pd-(l)1 inhibitor in the treatment of unresectable hepatocellular carcinoma: a retrospective study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492540/
https://www.ncbi.nlm.nih.gov/pubmed/37691972
http://dx.doi.org/10.2147/JHC.S423684
work_keys_str_mv AT yanghui efficacyandsafetyoftacecombinedwithlenvatinibandpdl1inhibitorinthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT yangtiequan efficacyandsafetyoftacecombinedwithlenvatinibandpdl1inhibitorinthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT qiuguangpin efficacyandsafetyoftacecombinedwithlenvatinibandpdl1inhibitorinthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy
AT liujie efficacyandsafetyoftacecombinedwithlenvatinibandpdl1inhibitorinthetreatmentofunresectablehepatocellularcarcinomaaretrospectivestudy